Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.
Also called NCT02624869
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 163 participants
- Sponsor
- Registry
-
NCT02624869 -
2015-002276-25
-
- Other papers using this trial's data
- Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Greece, Hungary, Italy, Malaysia, Netherlands, Norway, Poland, Portugal, Russia, Slovenia, South Africa, Spain, Switzerland, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02624869. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-10 (actual); primary completion 2021-06-01 (actual). Results posted on 2022-01-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
- Acronym
- HAUSER-OLE
- Condition
- Familial Hypercholesterolemia
- Intervention (Biological)
- Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02624869- Content hash
06e319e6f8472233e7f466a2dce518c9048f1d53c85f11bfaf8ac8a56df065cc